Indication for chemotherapy as initial treatment for early breast cancer has modified its surgical treatment, allowing breast preservation in most patients who develop clinical response.
1 However, in spite of high rates of pathologic complete response (pCR) in the axilla (26–66%), in particular in patients with human epidermal growth factor receptor 2 (HER2)+ and triple-negative tumor subtypes, there is still controversy about deescalation in surgical treatment of the axilla for patients with metastatic lymph nodes at diagnosis (pN+).
2 …